Financhill
Sell
34

ETNB Quote, Financials, Valuation and Earnings

Last price:
$8.57
Seasonality move :
-3.05%
Day range:
$8.37 - $8.82
52-week range:
$5.99 - $13.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.17x
Volume:
1.3M
Avg. volume:
1.8M
1-year change:
-35.65%
Market cap:
$1.3B
Revenue:
--
EPS (TTM):
-$3.43

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ETNB
89bio
-- -$0.76 -- -10.19% $27.55
AKRO
Akero Therapeutics
-- -$1.12 -- -16.23% $77.64
MDGL
Madrigal Pharmaceuticals
$97.8M -$4.12 -- -49.7% $401.67
MRNA
Moderna
$941.1M -$2.73 -19.37% -0.05% $54.14
NBY
NovaBay Pharmaceuticals
$2.5M -$0.24 14.03% -95.43% $0.85
PTN
Palatin Technologies
-- -$0.42 -100% -67.93% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ETNB
89bio
$8.70 $27.55 $1.3B -- $0.00 0% --
AKRO
Akero Therapeutics
$44.88 $77.64 $3.6B -- $0.00 0% --
MDGL
Madrigal Pharmaceuticals
$342.44 $401.67 $7.6B -- $0.00 0% --
MRNA
Moderna
$34.71 $54.14 $13.4B -- $0.00 0% 4.21x
NBY
NovaBay Pharmaceuticals
$0.64 $0.85 $3.1M -- $0.00 0% 0.07x
PTN
Palatin Technologies
$0.81 $7.00 $21.1M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ETNB
89bio
-- 2.587 -- --
AKRO
Akero Therapeutics
-- 3.401 -- --
MDGL
Madrigal Pharmaceuticals
13.48% 3.153 1.73% 5.79x
MRNA
Moderna
-- 0.488 -- 3.45x
NBY
NovaBay Pharmaceuticals
4.54% 0.646 1.51% 0.75x
PTN
Palatin Technologies
-- -1.737 -- 0.99x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ETNB
89bio
-- -$122M -- -- -- -$121.6M
AKRO
Akero Therapeutics
-- -$78M -- -- -- -$67.1M
MDGL
Madrigal Pharmaceuticals
$99.9M -$67M -55.1% -63.91% -54.12% -$104.7M
MRNA
Moderna
$217M -$1.2B -29.09% -29.09% -123.22% $303M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PTN
Palatin Technologies
-- -$5.1M -- -- -2356.3% -$4.8M

89bio vs. Competitors

  • Which has Higher Returns ETNB or AKRO?

    Akero Therapeutics has a net margin of -- compared to 89bio's net margin of --. 89bio's return on equity of -- beat Akero Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    AKRO
    Akero Therapeutics
    -- -$0.99 --
  • What do Analysts Say About ETNB or AKRO?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand Akero Therapeutics has an analysts' consensus of $77.64 which suggests that it could grow by 72.99%. Given that 89bio has higher upside potential than Akero Therapeutics, analysts believe 89bio is more attractive than Akero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    AKRO
    Akero Therapeutics
    9 0 0
  • Is ETNB or AKRO More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison Akero Therapeutics has a beta of -0.193, suggesting its less volatile than the S&P 500 by 119.294%.

  • Which is a Better Dividend Stock ETNB or AKRO?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Akero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or AKRO?

    89bio quarterly revenues are --, which are smaller than Akero Therapeutics quarterly revenues of --. 89bio's net income of -$118.4M is lower than Akero Therapeutics's net income of -$70M. Notably, 89bio's price-to-earnings ratio is -- while Akero Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus -- for Akero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
  • Which has Higher Returns ETNB or MDGL?

    Madrigal Pharmaceuticals has a net margin of -- compared to 89bio's net margin of -57.51%. 89bio's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -63.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    MDGL
    Madrigal Pharmaceuticals
    96.67% -$2.71 $872M
  • What do Analysts Say About ETNB or MDGL?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $401.67 which suggests that it could grow by 17.3%. Given that 89bio has higher upside potential than Madrigal Pharmaceuticals, analysts believe 89bio is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    MDGL
    Madrigal Pharmaceuticals
    9 2 0
  • Is ETNB or MDGL More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.403, suggesting its less volatile than the S&P 500 by 140.327%.

  • Which is a Better Dividend Stock ETNB or MDGL?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or MDGL?

    89bio quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $103.3M. 89bio's net income of -$118.4M is lower than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, 89bio's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    MDGL
    Madrigal Pharmaceuticals
    -- -- $103.3M -$59.4M
  • Which has Higher Returns ETNB or MRNA?

    Moderna has a net margin of -- compared to 89bio's net margin of -117.16%. 89bio's return on equity of -- beat Moderna's return on equity of -29.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    MRNA
    Moderna
    22.7% -$2.91 $10.9B
  • What do Analysts Say About ETNB or MRNA?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand Moderna has an analysts' consensus of $54.14 which suggests that it could grow by 55.97%. Given that 89bio has higher upside potential than Moderna, analysts believe 89bio is more attractive than Moderna.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    MRNA
    Moderna
    5 17 1
  • Is ETNB or MRNA More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

  • Which is a Better Dividend Stock ETNB or MRNA?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or MRNA?

    89bio quarterly revenues are --, which are smaller than Moderna quarterly revenues of $956M. 89bio's net income of -$118.4M is higher than Moderna's net income of -$1.1B. Notably, 89bio's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus 4.21x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    MRNA
    Moderna
    4.21x -- $956M -$1.1B
  • Which has Higher Returns ETNB or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to 89bio's net margin of -49.65%. 89bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About ETNB or NBY?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that 89bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe 89bio is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ETNB or NBY More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

  • Which is a Better Dividend Stock ETNB or NBY?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or NBY?

    89bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. 89bio's net income of -$118.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, 89bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    NBY
    NovaBay Pharmaceuticals
    0.07x -- $2.4M -$1.2M
  • Which has Higher Returns ETNB or PTN?

    Palatin Technologies has a net margin of -- compared to 89bio's net margin of -2357.27%. 89bio's return on equity of -- beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ETNB
    89bio
    -- -$1.02 --
    PTN
    Palatin Technologies
    -- -$0.12 -$111.5K
  • What do Analysts Say About ETNB or PTN?

    89bio has a consensus price target of $27.55, signalling upside risk potential of 216.61%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 764.09%. Given that Palatin Technologies has higher upside potential than 89bio, analysts believe Palatin Technologies is more attractive than 89bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    ETNB
    89bio
    8 2 0
    PTN
    Palatin Technologies
    0 0 0
  • Is ETNB or PTN More Risky?

    89bio has a beta of 1.346, which suggesting that the stock is 34.566% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

  • Which is a Better Dividend Stock ETNB or PTN?

    89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ETNB or PTN?

    89bio quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. 89bio's net income of -$118.4M is lower than Palatin Technologies's net income of -$2.4M. Notably, 89bio's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ETNB
    89bio
    -- -- -- -$118.4M
    PTN
    Palatin Technologies
    -- -- $350K -$2.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock